UNBS 5162

Drug Profile

UNBS 5162

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unibioscreen
  • Developer Drais Pharmaceuticals; Unibioscreen
  • Class Antineoplastics; Cytostatics; Naphthalimides
  • Mechanism of Action Angiogenesis inhibitors; Chemokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
  • 04 Mar 2010 UNBS 5162 is still in phase I development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top